Rhythm Pharmaceuticals Inc (RYTM) FinancialsRYTMFinancialRhythm Pharmaceuticals Inc

Evaluating the bottom line, Rhythm Pharmaceuticals, Inc. maintains a gross margin of 26.52%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -68.14%, while the net margin is -69.19%. These profitability ratios, combined with a Return on Equity (ROE) of -461.65%, provide a clear picture of how effectively RYTM converts its operational activities into shareholder value.

In the context of the broader market, RYTM competes directly with industry leaders such as ALKS and SYRE. With a market capitalization of $7.75B, it holds a significant position in the sector. When comparing efficiency, RYTM's gross margin of 26.52% stands against ALKS's 75.67% and SYRE's N/A. Such benchmarking helps identify whether Rhythm Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Rhythm Pharmaceuticals has shown fluctuating revenue growth, with Q2 2026 revenue at $71.3 million, a 47% year-over-year increase. However, the company continues to report significant net losses, with a net income of -$49.3 million in Q2 2026.